23:28 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Bone repair; tissue damage Patient sample and mouse studies suggest HMGB1 could treat bone fracture and muscle injury. In plasma samples from patients with fractured femurs, levels of HMGB1 were higher than in samples from...
19:51 , Jul 28, 2017 |  BC Week In Review  |  Company News

Feinstein grants Applied Immunotherapeutics rights to HMGB1 candidates

The Feinstein Institute for Medical Research (Manhasset, N.Y.) granted Applied Immunotherapeutics Inc. (Morris, Conn.) exclusive, worldwide rights to three preclinical candidates. Applied Immunotherapeutics gained rights to 2G7, a mAb against high mobility group box 1...
16:33 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Cell culture and mouse studies suggest HMGB1 could help treat white matter stroke. In oxygen- and glucose-deprived primary mouse oligodendrocytes, HMGB1 levels were higher than in oligodendrocytes cultured in normal conditions, and in a...
07:00 , Aug 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: High mobility group box 1 (HMGB1)

Neurology INDICATION: Neuroinflammation Rat and cell culture studies suggest inhibiting HMGB1 could help treat age-related neuroinflammation. Hippocampal levels of HMGB1 were higher in aged rats than in young rats. In microglia isolated from aged rats, pretreatment with...
08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nicotinic acetylcholine receptor α7 (CHRNA7)

Inflammation INDICATION: Shock / trauma Rat and mouse studies suggest agonizing CHRNA7 could help treat traumatic brain injury (TBI) by decreasing damage to the blood-brain barrier (BBB). In a rat model of TBI, a CHRNA7 agonist tool...
08:00 , Jan 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: High mobility group box 1 (HMGB1)

Cardiovascular disease INDICATION: Cardiomyopathy Mouse and patient studies suggest inhibiting HMGB1 could help treat inflammatory cardiomyopathy (myocarditis). Levels of HMGB1 were higher in cardiac tissue of patients with myocarditis and a mouse model of the indication...
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Toll-like receptor 4 (TLR4); high mobility group box 1 (HMGB1) In vitro and mouse studies suggest...
07:00 , Oct 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neuroinflammation High mobility group box 1 (HMGB1); HMGB2 Cell culture and mouse studies have identified a small...
07:00 , Jul 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver disease High mobility group box 1 (HMGB1) Studies in patient samples and mice suggest inhibiting...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Migraine; pain Caspase-1 (CASP1); high mobility group box 1 (HMGB1); NF-kB; pannexin 1 (PANX1) Mouse...